An observational study in Prostate Cancer, sponsored by Lantheus Medical Imaging. Active, not recruiting at 12 sites in United States. Open to male participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2026-09-15.
Sponsored by Lantheus Medical Imaging (part of Lantheus Holdings, Inc.) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Prostatic Neoplasms by Lantheus Holdings, Inc. — 1 open to participants now, 2 under way, 1 of them phase 3. Prostatic Neoplasms · Lantheus Holdings, Inc..
Among the 22 studies in Prostatic Neoplasms by Lantheus Holdings, Inc., this one is the only one that started in 2023, is one of 2 observational ones, and was the 20th registered.
7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →1 of the 22 studies in Prostatic Neoplasms by Lantheus Holdings, Inc. is open now, in 1 country. Recruiting first, the newest first:
Lantheus Medical Imaging · Sites in United States
Ages 18+ · Men only
By country, each count listing its studies:
Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 21 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 7 · Phase 3 4 · Phase 4 1
First in 2008; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 500 is above the median of 200 across 1,312 observational studies indexed under Prostatic Neoplasms.
Median enrollment 30 across the 20 interventional studies, 250 across the 2 observational. Of the 19 that completed or were terminated, 6 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Lantheus Medical Imaging, one of the names counted as Lantheus Holdings, Inc.. Under that name alone:
Lantheus Medical Imaging is the lead sponsor of 30 studies on the registry; 3 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 22 studies in Prostatic Neoplasms by Lantheus Holdings, Inc., from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this observational research is to assess the real-world clinical utility of PYLARIFY PET through evaluation of long-term outcomes for prostate cancer patients who are eligible for a PSMA/PET scan.
Participants will be enrolled at their physician's office at the time of referral for PYLARIFY PET and will be followed for up to 5 years. Data concerning their prostate cancer diagnostics and treatment will be collected at 6-month intervals.
Biologically male patients with confirmed prostate cancer referred to undergo a PSMA PET with PYLARIFY.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients must meet all the following inclusion criteria:
Patients meeting the enrollment criteria for either Cohort 1 or Cohort 2:
Cohort 1:
Patients who are newly diagnosed with prostate cancer (and have suspected per the physician's discretion per standard of care assessment) and have not yet initiated any prostate cancer treatment and are referred to undergo PYLARIFY PET for identification of suspected metastases.
OR
Patients who have previously received treatment for prostate cancer and are referred to undergo PYLARIFY PET or have received PYLARIFY PET for suspected recurrence of prostate cancer (based on an elevated PSA) within 60 days of consent to enroll in the registry
Exclusion Criteria:
Patients meeting any of the following exclusion criteria are not eligible for enrollment in this study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients who are newly diagnosed with prostate cancer (and have suspected metastases) and have not yet initiated any prostate cancer treatment and are referred to undergo PYLARIFY PET
Diagnostic Test: PYLARIFY
Patients who have previously received treatment for prostate cancer and are referred to undergo PYLARIFY PET or have received PYLARIFY PET for suspected recurrence of prostate cancer (based on an elevated PSA) within 60 days of consent to enroll in the registry
Diagnostic Test: PYLARIFY
PYLARIFY PET
Primary Objective
The objective of this registry is to assess the real-world clinical utility of PYLARIFY PET through evaluation of long-term outcomes for prostate cancer patients who are eligible for a PSMA/PET scan and for whom PYLARIFY imaging is incorporated into treatment recommendations and management plans.
Time frame: 5 years
Secondary Objective 1
To understand the demographic and clinical characteristics of patients referred for PYLARIFY PET.
Time frame: 5 years
Secondary Objective 2
To understand the impact of PYLARIFY PET results on healthcare resource utilization.
Time frame: 5 years
Secondary Objective 3
To understand the role of PYLARIFY PET in treatment change management for newly diagnosed prostate cancer patients.
Time frame: 5 years
Secondary Objective 4
To understand the utilization of PYLARIFY PET at very low PSA levels in patients with oligometastatic prostate cancer.
Time frame: 5 years
Secondary Objective 5
To understand racial and ethnic disparities in prostate cancer care.
Time frame: 5 years
Started May 2023 (actual). Primary completion is estimated for Feb 2031, 93 months after the start.
Of 109 industry-sponsored observational studies under Prostatic Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 65. This study's planned 93 months is above that.
Counting every sponsor, half of 651 studies reached it within 60 months; a quarter within 28 and three quarters within 141.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.